Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to provide written informed consent and can understand and agree to comply with the requirements of the study and the Schedule of Assessments~2. Age ≥ 18 years on the day of signing the informed consent form (or the legal age of consent in the jurisdiction in which the study is taking place)~3. At least 1 measurable lesion as defined by RECIST v1.1~4. Provide archival tumor tissue (formalin-fixed paraffin-embedded block \[FFPE\] with tumor tissue or unstained slides), if available.~5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1~6. Adequate hematologic and end-organ function~7. Participants with inactive/asymptomatic carrier, chronic, or active hepatitis B virus (HBV) must have HBV deoxyribonucleic acid (DNA) \< 500 IU/mL (or 2500 copies/mL) at Screening~8. Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and ≥ 120 days after the last dose of study drugs and have a negative serum pregnancy test ≤ 7 days of first dose of study drugs~9. Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 120 days after the last dose of study drugs~Exclusion Criteria:~1. Unacceptable toxicity on prior anti-PD-1/PD-L1 treatment~2. Active leptomeningeal disease or uncontrolled brain metastasis~3. Active autoimmune diseases or history of autoimmune diseases that may relapse~4. Any active malignancy ≤ 2 years~5. Any condition that required systemic treatment with either corticosteroids (\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before first dose of study drugs~6. History of interstitial lung disease, noninfectious pneumonitis or uncontrolled diseases, including pulmonary fibrosis, acute lung diseases, etc.~7. Severe chronic or active infections (including tuberculosis infection, etc.) requiring systemic antibacterial, antifungal or antiviral therapy, within 14 days prior to first dose of study drugs~8. Known history of human immunodeficiency virus (HIV) infection~9. Participants with active hepatitis C infection~10. Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of study drugs~11. Prior allogeneic stem cell transplantation or organ transplantation~12. Hypersensitivity to tislelizumab or sitravatinib, to any ingredient in the formulation, or to any component of the container~13. Bleeding or thrombotic disorders or use of anticoagulants such as warfarin or similar agents requiring therapeutic international normalized ratio (INR) monitoring within 6 months before first dose of study drugs~14. Concurrent participation in another therapeutic clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitravatinib + Tislelizumab (Type: EXPERIMENTAL): Sitravatinib 120 mg was administered orally once daily in combination with tislelizumab 200 mg intravenously (IV) once every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete